Stanford professor Russ Altman acknowledges that startups often fear regulators, but insists that in the biotech space, the FDA is keen to work with companies to bring products to market and advise startups as part of an open dialogue. In the context of AI-driven drug development, GSK senior VP and Global Head of AI/ML Kim Branson adds, an evolving conversation between industry and government will lead to new ways of ensuring the safe delivery of cutting-edge therapies.
Related
Maya Arengo,
Stanford University
Scaling a Climate Tech Company
An eCorner mini guide on the unique challenges that climate tech companies face when scaling, and how to overcome them.
Maya Arengo,
Stanford University
So You Want to Be a Climate Tech Entrepreneur
An eCorner mini guide on the current range of technologies within climate tech, and what kinds of funding for founders to secure.
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
Annie Hockey,
Column
Reimagining Fintech [Entire Talk]
The banking industry poses complex regulatory challenges for fintech entrepreneurs — but the space is ripe for innovation.
